3D printing and cryogenics could create new potential for artificial organs

[Image from Imperial College London]Researchers at Imperial College London have developed a technique to replicate biological structures using cryogenics and 3D printing. The research is a first from the university to create structures that are soft enough to replicate the mechanical properties of organs like the brain and lungs. The 3D printing technique could create replica organs and assist with tissue regeneration. Structure and softness of body tissues can be difficult to match, but when they are matched, the structures could be used in medical procedures to form scaffolds that can be a template for tissue regeneration. Damaged tissues would be bolstered to regrow, allowing the body to heal without issues like rejection from the body. Get the full story on our sister site, Medical Design &Outsourcing. The post 3D printing and cryogenics could create new potential for artificial organs appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Regenerative Medicine Research & Development Artificial Organs Imperial College London MedTech Source Type: news

Related Links:

Authors: Tissot A, Foureau A, Brosseau C, Danger R, Roux A, Bernasconi E, Gomez C, Durand M, Picard BR, Le Pavec J, Claustre J, Lacoste P, Benmerad M, Pain M, Siroux V, Royer PJ, Mordant P, Reynaud-Gaubert M, Kessler R, Brugière O, Mornex JF, Dromer C, Dahan M, Knoop C, Boussaud V, Koutsokera A, Botturi-Cavaillès K, Durand E, Loy J, Nicod L, Pison C, Brouard S, Blanc FX, Magnan A, consortium COLT PMID: 30100530 [PubMed - as supplied by publisher]
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
Jack Palmer, of Kansas City, Missouri, became the 20th infant under a year old to undergo a heart-lung transplant after he was born in January with a congenital heart defect.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
American Journal of Transplantation,Volume 0, Issue ja, -Not available-.
Source: American Journal of Transplantation - Category: Transplant Surgery Authors: Source Type: research
We report that the disruption of excitation-contraction coupling contributes to impaired force generation in the mouse model of Sod1 deficiency. Briefly, we found a significant reduction in sarcoplasmic reticulum Ca2+ ATPase (SERCA) activity as well as reduced expression of proteins involved in calcium release and force generation. Another potential factor involved in EC uncoupling in Sod1-/- mice is oxidative damage to proteins involved in the contractile response. In summary, this study provides strong support for the coupling between increased oxidative stress and disruption of cellular excitation contraction mac...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSIONS: Exogenous p51A gene can increase its expression in A549 and NCI-H1299 cells, suppress cell growth and induce cell apoptosis. Moreover, it can also cooperate with chemotherapy and reduce the dose and side-effect. p51A gene can suppress tumours in spite of p53 status and p21 gene might be involved. It might become a new promising therapeutic gene of tumours, which will make up for the limitation of p53 gene therapy. PMID: 30095026 [PubMed - as supplied by publisher]
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
The objective of this review is to present insights into pharmacotherapeutic techniques, which can be used for transdermal delivery of anticancer agents through skin due to its potential to create a new frontier in treatment of cancer. PMID: 30095010 [PubMed - as supplied by publisher]
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
With the development of medical technology, transplantation has prevailed and become an important tool in the treatment of disease. According to the WHO ’s statistics, as of 2015, approximately 120000 cases of solid organ transplantation have been performed globally. Renal transplantation is the most common, followed by liver transplantation, heart transplantation, lung transplantation, hematopoietic stem cell transplantation, etc. [1]. And, in re cipients of transplantation, seizures usually occur during the postoperative period [2,3].
Source: Seizure: European Journal of Epilepsy - Category: Neurology Authors: Tags: Review Source Type: research
This thirty-fifth adult lung and heart –lung transplant report summarizes data from 64,803 adult lung and 4,054 adult heart-lung transplants performed through June 30, 2017 and reported to the International Thoracic Organ Transplant Registry. With each year's report we now also provide more detailed analyses on a particular focus theme . Since 2013, these have been donor and recipient age; retransplantation; early graft failure; indication for transplant; and allograft ischemic time; and in 2018, multiorgan transplantation.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Original Clinical Science Source Type: research
AbstractPurpose of ReviewThere is a shortage of lungs available to meet the needs of patient who require lung transplantation. Ex vivo lung perfusion (EVLP) has allowed for the assessment and reconditioning of extended criteria and high-risk donor lungs, allowing for an increased volume of lung transplants. Recently, an invested interest in the utilization donation after cardiac death (DCD) donors has surfaced, in which EVLP has played an important role.Recent FindingsClinical studies have shown that EVLP can recondition donor lungs that initially would be unacceptable for transplantation. In a recent study, the interventi...
Source: Current Respiratory Care Reports - Category: Respiratory Medicine Source Type: research
Conditions:   Respiratory Failure;   Hepatitis C Intervention:   Drug: Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 12 weeks Sponsor:   Massachusetts General Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Lung Transplant | Medical Devices | Neurology